BioRegenis Biomolecular Gen
Computational biotechnology
Technological maturity
17%
TRL level
TRL 2
BRG-BMG
- TRL 1
- TRL 2
- TRL 3
- TRL 4
- TRL 5
- TRL 6
- TRL 7
- TRL 8
- TRL 9
Software for the computational analysis of molecules and products, bringing the feasibility assessment forward to the early stages of development.
The TRL scale
We do not use clinical trial phase nomenclature, which would be inappropriate for devices, software and cosmetic products. The TRL 1–9 scale describes technological maturity, from a basic principle observed to a system proven in a real operational environment.
- TRL 10–11%
- TRL 212–22%
- TRL 323–33%
- TRL 434–44%
- TRL 545–55%
- TRL 656–66%
- TRL 767–77%
- TRL 878–88%
- TRL 989–100%
- The TRL 1–9 scale measures the technological maturity of a programme: the percentage marks its position along that scale, not its distance from market entry. Programme status updated August 2026.
The problem. The preliminary assessment of molecules and products currently requires fragmented steps across different tools, with results that are hard to compare and an effort that often discourages the analysis exactly where it would be most useful: at the start.
The BioRegenis solution. Software dedicated to the computational analysis of molecules and products in the nutraceutical, medical device and cosmetic fields, with the aim of bringing the feasibility assessment forward to the early stages of development.
State of progress.
Development — under way, 30%
Prototype — under way, 30%
An early-stage programme. We publish it with its real status because it is part of our technology strategy, not because it is close to release.
Next milestone. Definition of the functional architecture and delivery of a first demonstration prototype.
Expected applications. Internal support for the development of BioRegenis programmes and, in perspective, use as a tool for third parties.
Intellectual property. Proprietary software under development by BioRegenis Srl.